S&P 500   3,157.87 (+0.52%)
DOW   28,035.78 (+0.45%)
QQQ   205.86 (+0.43%)
AAPL   269.69 (-0.40%)
FB   200.75 (-0.75%)
MSFT   151.96 (+0.17%)
GOOGL   1,344.18 (+-0.01%)
AMZN   1,752.00 (+0.19%)
CGC   20.96 (+3.51%)
GE   11.35 (+3.46%)
T   38.39 (+0.55%)
AMD   41.31 (+4.66%)
ACB   2.58 (+5.31%)
F   9.27 (+1.76%)
BAC   34.36 (+2.14%)
DIS   147.49 (-0.07%)
S&P 500   3,157.87 (+0.52%)
DOW   28,035.78 (+0.45%)
QQQ   205.86 (+0.43%)
AAPL   269.69 (-0.40%)
FB   200.75 (-0.75%)
MSFT   151.96 (+0.17%)
GOOGL   1,344.18 (+-0.01%)
AMZN   1,752.00 (+0.19%)
CGC   20.96 (+3.51%)
GE   11.35 (+3.46%)
T   38.39 (+0.55%)
AMD   41.31 (+4.66%)
ACB   2.58 (+5.31%)
F   9.27 (+1.76%)
BAC   34.36 (+2.14%)
DIS   147.49 (-0.07%)
S&P 500   3,157.87 (+0.52%)
DOW   28,035.78 (+0.45%)
QQQ   205.86 (+0.43%)
AAPL   269.69 (-0.40%)
FB   200.75 (-0.75%)
MSFT   151.96 (+0.17%)
GOOGL   1,344.18 (+-0.01%)
AMZN   1,752.00 (+0.19%)
CGC   20.96 (+3.51%)
GE   11.35 (+3.46%)
T   38.39 (+0.55%)
AMD   41.31 (+4.66%)
ACB   2.58 (+5.31%)
F   9.27 (+1.76%)
BAC   34.36 (+2.14%)
DIS   147.49 (-0.07%)
S&P 500   3,157.87 (+0.52%)
DOW   28,035.78 (+0.45%)
QQQ   205.86 (+0.43%)
AAPL   269.69 (-0.40%)
FB   200.75 (-0.75%)
MSFT   151.96 (+0.17%)
GOOGL   1,344.18 (+-0.01%)
AMZN   1,752.00 (+0.19%)
CGC   20.96 (+3.51%)
GE   11.35 (+3.46%)
T   38.39 (+0.55%)
AMD   41.31 (+4.66%)
ACB   2.58 (+5.31%)
F   9.27 (+1.76%)
BAC   34.36 (+2.14%)
DIS   147.49 (-0.07%)
Log in

NASDAQ:ALKS - Alkermes Stock Price, Forecast & News

$21.25
+0.32 (+1.53 %)
(As of 12/12/2019 01:46 PM ET)
Today's Range
$20.81
Now: $21.25
$21.38
50-Day Range
$18.69
MA: $20.34
$21.70
52-Week Range
$17.11
Now: $21.25
$37.75
Volume523,281 shs
Average Volume2.06 million shs
Market Capitalization$3.35 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.77
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALKS
CUSIPG0176710
Phone353-1772-8000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.09 billion
Cash Flow$0.60 per share
Book Value$7.54 per share

Profitability

Net Income$-139,310,000.00

Miscellaneous

Employees2,300
Market Cap$3.35 billion
Next Earnings Date2/13/2020 (Estimated)
OptionableOptionable

Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.


Alkermes (NASDAQ:ALKS) Frequently Asked Questions

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

How were Alkermes' earnings last quarter?

Alkermes Plc (NASDAQ:ALKS) announced its earnings results on Wednesday, October, 23rd. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.17. The business earned $255.24 million during the quarter, compared to the consensus estimate of $252.65 million. Alkermes had a negative net margin of 18.71% and a negative return on equity of 6.08%. Alkermes's quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.07 earnings per share. View Alkermes' Earnings History.

When is Alkermes' next earnings date?

Alkermes is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Alkermes.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes updated its FY19 earnings guidance on Wednesday, October, 23rd. The company provided earnings per share (EPS) guidance of $0.44-0.57 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.37. The company issued revenue guidance of $1.14-1.19, compared to the consensus revenue estimate of $1.18 billion.

What price target have analysts set for ALKS?

10 brokerages have issued 1 year price objectives for Alkermes' shares. Their forecasts range from $20.00 to $34.00. On average, they expect Alkermes' stock price to reach $26.44 in the next twelve months. This suggests a possible upside of 24.4% from the stock's current price. View Analyst Price Targets for Alkermes.

What is the consensus analysts' recommendation for Alkermes?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 2 sell ratings, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alkermes.

What are Wall Street analysts saying about Alkermes stock?

Here are some recent quotes from research analysts about Alkermes stock:
  • 1. According to Zacks Investment Research, "Alkermes posted narrower-than-expected loss and sales beat estimates in the first quarter of 2019. With the increasing traction of Aristada in the market, the company continues to emerge as a leader in the treatment of schizophrenia. This year will be an important one for the company’s late-stage pipeline, highlighted by the planned submission of the NDA for ALKS 3831 and the regulatory review of the recently submitted NDA for diroximel fumarate for multiple sclerosis, with action expected in the fourth quarter. The company also expects to release data from ALKS 4230's anti-tumor response study in 2019. However, Alkermes is highly dependent on manufacturing and/or royalty revenues from partners, which is a concern. Shares have underperformed the industry year to date. Alkermes has a positive record of earnings surprises in recent quarters." (7/19/2019)
  • 2. HC Wainwright analysts commented, "Valuation Our $28 price target for Alkermes is based on our sum-of-the-parts NPV valuation based on each of the company’s marketed products and pipeline assets. Our DCF model utilizes a discount rate of 13.1% based on the company’s WACC (Beta of 1.9, equity risk premium of 6.7%)." (5/31/2019)

Has Alkermes been receiving favorable news coverage?

Media coverage about ALKS stock has trended very negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alkermes earned a daily sentiment score of -3.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Alkermes.

Are investors shorting Alkermes?

Alkermes saw a drop in short interest in the month of November. As of November 29th, there was short interest totalling 6,370,000 shares, a drop of 15.5% from the November 14th total of 7,540,000 shares. Based on an average daily volume of 1,590,000 shares, the short-interest ratio is presently 4.0 days. Currently, 4.1% of the company's shares are short sold. View Alkermes' Current Options Chain.

Who are some of Alkermes' key competitors?

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Celgene (CELG), Netflix (NFLX), AbbVie (ABBV), NVIDIA (NVDA), Alibaba Group (BABA), Starbucks (SBUX), Gilead Sciences (GILD), Intel (INTC), Advanced Micro Devices (AMD) and Cisco Systems (CSCO).

Who are Alkermes' key executives?

Alkermes' management team includes the folowing people:
  • Mr. Richard F. Pops, Chairman & CEO (Age 57)
  • Dr. Floyd E. Bloom, Co-Founder & Director (Age 82)
  • Mr. James M. Frates, Sr. VP & CFO (Age 52)
  • Mr. David Joseph Gaffin, Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 47)
  • Dr. Craig C. Hopkinson, Sr. VP of Medicines Devel. & Medical Affairs and Chief Medical Officer (Age 51)

Who are Alkermes' major shareholders?

Alkermes' stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (3.38%), First Trust Advisors LP (1.66%), California Public Employees Retirement System (0.22%), Alps Advisors Inc. (0.20%), California State Teachers Retirement System (0.16%) and Russell Investments Group Ltd. (0.14%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Floyd E Bloom, Iain Michael Brown, James M Frates, Laurie Keating, Mark Stejbach, Michael J Landine, Nancy Wysenski, Paul J Mitchell, Richard F Pops and Shane Cooke. View Institutional Ownership Trends for Alkermes.

Which institutional investors are selling Alkermes stock?

ALKS stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, First Trust Advisors LP, Squarepoint Ops LLC, State of New Jersey Common Pension Fund D, Teacher Retirement System of Texas, Alps Advisors Inc., Daiwa Securities Group Inc. and SG Americas Securities LLC. Company insiders that have sold Alkermes company stock in the last year include David Joseph Gaffin, David W Anstice, Michael J Landine, Paul J Mitchell and Richard F Pops. View Insider Buying and Selling for Alkermes.

Which institutional investors are buying Alkermes stock?

ALKS stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Rhenman & Partners Asset Management AB, Russell Investments Group Ltd., Moloney Securities Asset Management LLC, Fox Run Management L.L.C., Steward Partners Investment Advisory LLC, Fjarde AP Fonden Fourth Swedish National Pension Fund and Nisa Investment Advisors LLC. View Insider Buying and Selling for Alkermes.

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $21.25.

How big of a company is Alkermes?

Alkermes has a market capitalization of $3.35 billion and generates $1.09 billion in revenue each year. The company earns $-139,310,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Alkermes employs 2,300 workers across the globe.View Additional Information About Alkermes.

What is Alkermes' official website?

The official website for Alkermes is http://www.alkermes.com/.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]


MarketBeat Community Rating for Alkermes (NASDAQ ALKS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  571 (Vote Outperform)
Underperform Votes:  428 (Vote Underperform)
Total Votes:  999
MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote "Outperform" if you believe ALKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel